EP0401747A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Use of rapamycin and derivatives and prodrugs thereof in the manufacture of a medicament for inhibiting transplant rejection in mammals
Assignee: Individual
•
Filing: 1990-06-05
•
Granted: —
•
Expires: 2010-06-05
Abstract
Abstract This invention provides a method of inhibiting organ or tissue transplant rejection in a mammal in need thereof, comprising administering to said mammal a transplant rejection inhibiting amount of rapamycin. Also disclosed is a method of inhibiting organ or tissue transplant rejection in a mammal in need thereof, comprising administering to said mammal (a) an amount of rapamycin in combination with (b) an amount of one or more other chemotherapeutic agents for inhibiting transplant rejection, e.g., azathioprine, corticosteroids, cyclosporin and FK506, said amounts of (a) and (b) together being effective to inhibit transplant rejection and to maintain inhibition of transplant rejection.
Inventors
- 👤 Roy Calne
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 10:20
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61K31/435; A61K31/44; A61K31/445; A61K31/56; A61K31/57; A61K38/00; A61K38/04; A61K38/12; A61K38/13; A61P; A61P37/00; A61P37/02; A61P37/06
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
28 words
A composition for inhibiting organ or tissue transplant rejection in a mammal in need thereof, comprising rapamycin for administration to said mammal in a transplant rejection inhibiting amount.
Claim 2
Dependent Claim
28 words
A composition for inhibiting organ or tissue transplant rejection in a mammal in need thereof, comprising rapamycin for administration to said mammal in a transplant rejection inhibiting amount.
Claim 3
Dependent Claim
20 words
A composition according to claim 1, wherein the amount of rapamycin further is effective to maintain inhibition of transplant rejection.
Claim 4
Dependent Claim
50 words
A composition according to claim 1 or 2, comprising a combination of (a) an amount of rapamycin (b) an amount of one or more chemotherapeutic agents for inhibiting transplant rejection, said amounts of (a) and (b) together being effective to inhibit transplant rejection and to maintain inhibition of transplant rejection.
Claim 5
Dependent Claim
29 words
The composition according to claim 3, wherein said chemotherapeutic agent is selected from the group consisting of azathioprine, corticosteroids, cyclosporin and FK506 and combinations of any of the foregoing.
Claim 6
Dependent Claim
25 words
The composition according to any one of claims 1 to 4, wherein said transplant rejection inhibiting amount comprises from about 0.5 to about 50 mg/kg/day.
Claim 7
Dependent Claim
22 words
The composition according to any one of claims 1 to 4, wherein said amount comprises from about 1 to about 5 mg/kg/day.
Claim 8
Dependent Claim
17 words
The composition according to claim 5, wherein said amount comprises from about 0.01 to about 10 mg/kg/day.
Claim 9
Dependent Claim
17 words
The composition according to claim 7, wherein said amount comprises from about 0.025 to about 5 mg/kg/day.
Claim 10
Dependent Claim
37 words
The composition according to any one of claims 1 to 8, wherein said transplant rejection inhibiting amount of rapamycin is administered to said mammal for a period of time comprising from about 1 to about 180 days.
Claim 11
Dependent Claim
21 words
The composition according to any one of claims 1 to 9, wherein said rapamycin is formulated in an oral dosage form.
Claim 12
Dependent Claim
21 words
The composition according to any one of claims 1 to 9, wherein said rapamycin is formulated in a parenteral dosage form.
Claim 13
Dependent Claim
22 words
Use of rapamycin for the preparation of a medicament for inhibiting organ or tissue transplant rejection in a mammal in need thereof.
Claim 14
Dependent Claim
22 words
Use of rapamycin for the preparation of a medicament for inhibiting organ or tissue transplant rejection in a mammal in need thereof.
Claim 15
Dependent Claim
22 words
Use of rapamycin according to claim 12, wherein the medicament further serves to maintain said inhibition of organ or tissue transplant rejection.
Claim 16
Dependent Claim
36 words
Use of rapamycin according to claim 12 or 13, wherein the medicament further contains an amount of one or more other chemotherapeutic agents for inhibiting organ or tissue transplant rejection in a mammal in need thereof.
Claim 17
Dependent Claim
30 words
Use of rapamycin according to claim 14, wherein said chemotherapeutic agent is selected from the group consisting of azathioprine, corticosteroids, cyclosporin, FK506, OKT3 and combinations of any of the foregoing.
Claim 18
Dependent Claim
35 words
Use of rapamycin according to any one of claims 12 to 15, wherein said medicament is formulated for administration of rapamycin to said mammal in an amount of from about 0.5 to about 50 mg/kg/day.
Claim 19
Dependent Claim
23 words
Use of rapamycin according to any one of claims 12 to 15, wherein said amount comprises from about 1 to about 5 mg/kg/day.
Claim 20
Dependent Claim
18 words
Use of rapamycin according to claim 16, wherein said amount comprises from about 0.01 to about 10 mg/kg/day.
Claim 21
Dependent Claim
18 words
Use of rapamycin according to claim 18, wherein said amount comprises from about 0.025 to about 5 mg/kg/day.
Claim 22
Dependent Claim
32 words
Use of rapamycin according to any one of claims 12 to 19, said medicament being administered to said mammal for a period of time comprising from about 1 to about 180 days.
Claim 23
Dependent Claim
23 words
The use of rapamycin according to any one of claims 12 to 20, wherein said rapamycin is administered in an oral dosage form.
Claim 24
Dependent Claim
23 words
The use of rapamycin according to any one of claims 12 to 20, wherein said rapamycin is administered in a parenteral dosage form.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.